TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from COSCIENS Biopharma ( (TSE:CSCI) ).
On December 1, 2025, COSCIENS Biopharma Inc. announced an exclusive distribution agreement with Wuzhou Drug International for the commercialization of Macrilen® in the Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore. This partnership aims to leverage the ‘Hong Kong and Macao Medicine and Equipment Connect’ policy for expedited market access, with Wuzhou responsible for registration, importation, and commercialization. The agreement represents a strategic move for COSCIENS to expand its market presence in Asia, addressing a significant unmet need for oral diagnostic options for AGHD and potentially enhancing revenue streams.
More about COSCIENS Biopharma
COSCIENS Biopharma Inc. is a life sciences company focused on pharmaceutical therapies, diagnostic products, and natural ingredient solutions. The company develops natural, plant-based active ingredients and commercializes pharmaceutical and diagnostic products, including Macrilen®, an FDA and EMA approved oral test for diagnosing Adult Growth Hormone Deficiency (AGHD).
YTD Price Performance: -23.41%
Average Trading Volume: 3,551
Technical Sentiment Signal: Sell
Current Market Cap: C$9.58M
For detailed information about CSCI stock, go to TipRanks’ Stock Analysis page.